SUPERNUS PHARMACEUTICALS, INC. Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $48.00 thousand as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2018-03-01
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $48.00K.
- 2017-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $286.00K.
- 2017-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $229.00K.
- 2017-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $135.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2017-12-31 | $48.00K 10-K · filed 2018-03-01 |
| 2017-09-30 | $286.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $229.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $135.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $86.00K 10-K · filed 2018-03-01 |
| 2016-09-30 | $464.00K 10-Q · filed 2017-01-20 |
| 2016-06-30 | $597.00K 10-Q/A · filed 2017-01-23 |
| 2016-03-31 | $300.00K 10-Q/A · filed 2017-01-20 |
| 2015-12-31 | $5.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $23.00K 10-Q/A · filed 2017-01-20 |
| 2015-06-30 | $10.00K 10-Q/A · filed 2017-01-23 |
| 2015-03-31 | $15.00K 10-Q/A · filed 2017-01-20 |
| 2014-12-31 | $4.00K 10-Q/A · filed 2017-01-20 |
| 2014-09-30 | $14.00K 10-Q/A · filed 2017-01-20 |
| 2013-12-31 | $33.00K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |